Market Research Logo

Multiple Sclerosis: Update Bulletin [March 2016]

Multiple Sclerosis: Update Bulletin [March 2016]

Introduction

Gain new KOL insights on the latest events happening in multiple sclerosis (MS):

Topics covered include opinions about the discontinuation of Teva’s/Active Biotech’s higher-dose laquinimod Phase III studies; reactions to European and Canadian regulatory authority recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod), as well as opinions on GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis.
Key Questions Answered in this Update Bulletin:

  • How do KOLs feel about the continuation of lower-dose laquinimod studies?
  • How optimistic are KOLs regarding laquinimod’s approval?
  • What are KOLs’ reactions to European and Canadian recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod)?
  • What impact will these label changes have on prescriptions of Gilenya?
  • What threats will Gilenya face in the future?
  • How optimistic are KOLs about GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report